A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney

Trial Profile

A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs BB 3 (Primary)
  • Indications Delayed graft function
  • Focus Registrational; Therapeutic Use
  • Acronyms GIFT
  • Sponsors Angion Biomedica
  • Most Recent Events

    • 17 Aug 2017 Planned End Date changed from 1 May 2018 to 1 Jul 2019.
    • 17 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2018.
    • 17 Jan 2017 Planned End Date changed from 1 Oct 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top